Table 1.
Baseline patient characteristics
| Characteristics | Evaluable population (n=329) |
| Age, years | 61.4±10.0 |
| Male | 200/329 (60.8) |
| Body mass index | 27.6±4.2 |
| Left ventricular ejection fraction, % | 61.6±6.9 |
| Left atrial diameter, mm | 39.1±5.2 |
| CHA2DS2-VASc score | 1.6±1.4 |
| Patient medical history | |
| Atrial fibrillation duration, months | 22.0 (6.0, 60.0) |
| Atrial flutter | 63/329 (19.1) |
| Hypertension | 138/329 (41.9) |
| Type II diabetes | 22/329 (6.7) |
| Coronary disease | 34/329 (10.3) |
| Thromboembolic events | 19/329 (5.8) |
| Congestive heart failure | 9/329 (2.7) |
| NYHA class I | 4/329 (1.2) |
| NYHA class II | 5/329 (1.5) |
| Previously failed anti-arrhythmic drug(s) | |
| Number of failed anti-arrhythmic drugs | 1.7±0.7 |
| Failed any class I/III anti-arrhythmic drug | 242/329 (73.6) |
| Failed any class II/IV anti-arrhythmic drug | 232/329 (70.5) |
Numbers in the table are represented as mean±SD, n/N (%) or median (IQR).
NYHA, New York Heart Association.